Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008398 · ClinicalTrials.gov registry record · Phase 3
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00008398: Completed Phase 3 study, sponsored by Radiation Therapy Oncology Group.
NCT00008398 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00008398, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of sargramostim in decreasing mucositis in patients who are receiving radiation therapy for head and neck cancer.
Interventions
- PROCEDURE quality-of-life assessment
- RADIATION radiation therapy
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-10 |
| Phase | Phase 3 |
What the finished NCT00008398 record still lists
NCT00008398 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT00008398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00008398 about?
NCT00008398 is a clinical study titled "Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer". RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by radiation therapy. PURPOSE: Randomized phase III trial to determine the ...
What is the current status of trial NCT00008398?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-10.
What interventions are being tested in trial NCT00008398?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), radiation therapy (RADIATION), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00008398?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia